PH12019500609B1 - Cd123 binding proteins and related compositions and methods - Google Patents

Cd123 binding proteins and related compositions and methods

Info

Publication number
PH12019500609B1
PH12019500609B1 PH1/2019/500609A PH12019500609A PH12019500609B1 PH 12019500609 B1 PH12019500609 B1 PH 12019500609B1 PH 12019500609 A PH12019500609 A PH 12019500609A PH 12019500609 B1 PH12019500609 B1 PH 12019500609B1
Authority
PH
Philippines
Prior art keywords
molecules
methods
binding
binding proteins
binding domain
Prior art date
Application number
PH1/2019/500609A
Other languages
English (en)
Other versions
PH12019500609A1 (en
Inventor
David Bienvenue
John W Blankenship
Gabriela Hernandez-Hoyos
Catherine J Mcmahan
Danielle Mitchell
Peter Pavlik
Elaine T Sewell
Original Assignee
Aptevo Res & Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Res & Development Llc filed Critical Aptevo Res & Development Llc
Publication of PH12019500609A1 publication Critical patent/PH12019500609A1/en
Publication of PH12019500609B1 publication Critical patent/PH12019500609B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2019/500609A 2016-09-21 2017-09-21 Cd123 binding proteins and related compositions and methods PH12019500609B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662397736P 2016-09-21 2016-09-21
US201762466192P 2017-03-02 2017-03-02
PCT/US2017/052808 WO2018057802A1 (en) 2016-09-21 2017-09-21 Cd123 binding proteins and related compositions and methods

Publications (2)

Publication Number Publication Date
PH12019500609A1 PH12019500609A1 (en) 2019-06-03
PH12019500609B1 true PH12019500609B1 (en) 2024-02-21

Family

ID=61690646

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2019/500609A PH12019500609B1 (en) 2016-09-21 2017-09-21 Cd123 binding proteins and related compositions and methods

Country Status (17)

Country Link
US (4) US11242400B2 (https=)
EP (1) EP3515491A4 (https=)
JP (2) JP7224289B2 (https=)
KR (1) KR102559732B1 (https=)
CN (1) CN109952112B (https=)
AU (1) AU2017331256B2 (https=)
BR (1) BR112019005333A2 (https=)
CA (1) CA3037688A1 (https=)
CO (1) CO2019003951A2 (https=)
IL (1) IL265484B2 (https=)
MX (2) MX2019003225A (https=)
MY (1) MY194290A (https=)
PH (1) PH12019500609B1 (https=)
SG (1) SG10202102846SA (https=)
UA (1) UA127450C2 (https=)
WO (1) WO2018057802A1 (https=)
ZA (1) ZA201902323B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
JP2022532868A (ja) * 2019-05-04 2022-07-20 インヒブルクス インコーポレイテッド Ｃｄ１２３結合性ポリペプチド及びその使用
EP3753954A1 (en) * 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
US20220242962A1 (en) * 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
CN110804096B (zh) * 2019-11-21 2021-07-06 深圳普瑞金生物药业有限公司 Cd123单域抗体、核苷酸序列、表达载体及试剂盒
BR112022013730A2 (pt) * 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
WO2021146328A1 (en) * 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
CN111349163B (zh) 2020-02-05 2024-07-16 北京智仁美博生物科技有限公司 针对cd123的单克隆抗体
US20230273126A1 (en) * 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN111732635B (zh) * 2020-06-22 2022-03-22 中国医学科学院基础医学研究所 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用
EP4232159A1 (en) * 2020-10-23 2023-08-30 Icahn School of Medicine at Mount Sinai Sars-cov-2 antibodies and uses thereof
IL303328A (en) * 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
US20240076392A1 (en) * 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof
EP4341291A1 (en) * 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
CN116162148B (zh) * 2021-11-24 2025-09-09 中山光度生物医药有限公司 多特异性配体结合分子及其应用
CN116836282B (zh) * 2023-02-13 2024-03-29 北京艺妙神州医药科技有限公司 抗体、嵌合抗原受体及其用途
CN117660325B (zh) * 2024-01-31 2024-04-19 苏州科为康生物医药科技有限公司 一种制备脐带血msc的培养基及其方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20050009743A1 (en) 2001-07-26 2005-01-13 Sundquist Wesley I In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation
JP2006508638A (ja) * 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
WO2005058251A2 (en) 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
AU2006210660B2 (en) 2005-02-01 2011-12-01 Morphosys Ag Libraries and methods for isolating antibodies
JP2008539785A (ja) * 2005-05-16 2008-11-20 モルフォテック、インク． 所望の表現型を示す細胞を選択するために制御されたベクター
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US7949480B2 (en) 2006-06-14 2011-05-24 Simphotek, Inc. Method for determining an interaction between an electromagnetic radiation and a material
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
EP2187971A2 (en) 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services A fold-back diabody diphtheria toxin immunotoxin and methods of use
US20110293619A1 (en) * 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
JP6509724B2 (ja) * 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
PT2850106T (pt) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3
WO2014143807A2 (en) * 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
MA40609B1 (fr) * 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US20180022819A1 (en) 2015-02-11 2018-01-25 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
WO2017053469A2 (en) * 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017210443A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
BR112022013730A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas

Also Published As

Publication number Publication date
PH12019500609A1 (en) 2019-06-03
CN109952112B (zh) 2024-09-06
AU2017331256B2 (en) 2024-11-07
US20220363773A1 (en) 2022-11-17
WO2018057802A1 (en) 2018-03-29
AU2017331256A1 (en) 2019-04-04
ZA201902323B (en) 2023-07-26
US20190071513A1 (en) 2019-03-07
NZ751479A (en) 2025-09-26
IL265484B1 (en) 2025-09-01
MX2022015847A (es) 2023-01-24
US12441798B2 (en) 2025-10-14
CO2019003951A2 (es) 2019-04-30
EP3515491A1 (en) 2019-07-31
CA3037688A1 (en) 2018-03-29
EP3515491A4 (en) 2020-09-16
JP2023058573A (ja) 2023-04-25
KR20190069437A (ko) 2019-06-19
US10676533B2 (en) 2020-06-09
JP2019531764A (ja) 2019-11-07
JP7224289B2 (ja) 2023-02-17
UA127450C2 (uk) 2023-08-30
US11939392B2 (en) 2024-03-26
IL265484A (en) 2019-05-30
CN109952112A (zh) 2019-06-28
MY194290A (en) 2022-11-26
US11242400B2 (en) 2022-02-08
BR112019005333A2 (pt) 2019-06-11
US20200165346A1 (en) 2020-05-28
IL265484B2 (en) 2026-01-01
MX2019003225A (es) 2019-06-10
US20240343801A1 (en) 2024-10-17
KR102559732B1 (ko) 2023-07-26
SG10202102846SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
PH12018500520A1 (en) Cd3 binding polypeptides
WO2016094873A3 (en) Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2024008521A (es) Aglutinantes de albumina serica mejorados.
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
WO2016130819A3 (en) Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
HK1245287A1 (zh) IL13RAα2结合剂和其在癌症治疗中的用途
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
PH12017500892A1 (en) Antigen binding molecules comprising a tnf family ligand trimer
BR112018008983A2 (pt) moléculas de ligação específicas para asct2 e seus usos
NZ759601A (en) Aggrecan binding immunoglobulins
MX2017001263A (es) Fragmentos de anticuerpos radiomarcados para usarse en la prevencion y/o tratamiento de cancer.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EP3974443A3 (en) Peptides derived from melanoma-associated antigen b2 (mageb2)
WO2017089780A3 (en) Peptides
EA201990773A1 (ru) Cd123-связывающие белки и относящиеся к ним композиции и способы
WO2017089781A3 (en) Peptides derived from abnormal spindle-like microcephaly-associated protein (aspm) and complexes comprising such peptides bound to mhc molecules
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
EA201991139A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением
EA201990488A1 (ru) Новые t-клеточные рецепторы и иммунотерапия с их применением